The Importance of Sphingomyelin Phosphodiesterase Acid-Like 3b (SMPDL-3b) Levels in Kidney Biopsy Specimens of Children With Nephrotic Syndrome

References

• Yoo T-H, Pedigo CE, Guzman J, Correa-Medina M, Wei C, Villarreal R, Mitrofanova A, Leclercq F, Faul C, Li J, et al. Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease. J Am Soc Nephrol. 2015;26(1):133–47. doi:10.1681/ASN.2013111213.
   PubMed Web of Science ®Google Scholar
• Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, Li J, Mattiazzi A, Ciancio G, Chen L, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011;3(85):85ra46. doi:10.1126/scitranslmed.3002231.
   PubMed Web of Science ®Google Scholar
• Merscher S, Fornoni A. Podocyte pathology and nephropathy - sphingolipids in glomerular diseases. Front Endocrinol (Lausanne). 2014;5:127. doi:10.3389/fendo.2014.00127.
   PubMed Web of Science ®Google Scholar
• Girişgen İ, Yüksel S, Pekal Y. Rituximab experience in children with nephrotic syndrome: what have we observed differently. Turk pediatri arsivi. 2020;55(1):60–6.
   PubMedGoogle Scholar
• Kallash M, Smoyer WE, Mahan JD. Rituximab use in the management of childhood nephrotic syndrome. Front Pediatr. 2019;7:178. doi:10.3389/fped.2019.00178.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Tsugawa K, Tsuruga K, Imaizumi T, Tanaka H. Urinary excretion of sphingomyelinase phosphodiesterase acid-like 3b in children with intractable nephrotic syndrome. Pediatr Int. 2017;59(10):1112–5. doi:10.1111/ped.13355.
   PubMed Web of Science ®Google Scholar
• Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am. 1987;34(3):571–90. doi:10.1016/s0031-3955(16)36251-4.
   PubMed Web of Science ®Google Scholar
• Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, Cook HT, Fervenza FC, Gibson KL, Glassock RJ, et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int. 2021;100(4):753–79. doi:10.1016/j.kint.2021.05.015.
   PubMed Web of Science ®Google Scholar
• Yilmaz AF, Kaymaz B, Aktan Ç, Soyer N, Kosova B, Güneş A, Şahin F, Cömert M, Saydam G, Vural F, et al. Determining expression of miRNAs that potentially regulate STAT5A and 5B in dasatinib-sensitive K562 cells. Turk J Biol. 2017;41(6):926–34. doi:10.3906/biy-1705-66.
   PubMed Web of Science ®Google Scholar
• Tokgun PE, Tokgun O, Kurt S, Tomatir AG, Akca H. MYC-driven regulation of long non-coding RNA profiles in breast cancer cells. Gene. 2019;714:143955. doi:10.1016/j.gene.2019.143955.
   PubMed Web of Science ®Google Scholar
• Han KH, Kim SH. Recent advances in treatments of primary focal segmental glomerulosclerosis in children. Biomed Res Int. 2016;2016:3053706. doi:10.1155/2016/3053706.
   PubMed Web of Science ®Google Scholar
• Trautmann A, Vivarelli M, Samuel S, Gipson D, Sinha A, Schaefer F, Hui NK, Boyer O, Saleem MA, Feltran L, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2020;35(8):1529–1561. doi:10.1007/s00467-020-04519-1.
   PubMed Web of Science ®Google Scholar
• Iijima K, Sako M, Nozu K. Rituximab for nephrotic syndrome in children. Clin Exp Nephrol. 2017;21(2):193–202. doi:10.1007/s10157-016-1313-5.
   PubMed Web of Science ®Google Scholar
• Koskimies O, Vilska J, Rapola J, Hallman N. Long-term outcome of primary nephrotic syndrome. Arch Dis Child. 1982;57(7):544–8. doi:10.1136/adc.57.7.544.
   PubMed Web of Science ®Google Scholar
• Lombel RM, Gipson DS, Hodson EM. Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr Nephrol. 2013;28(3):415–26. doi:10.1007/s00467-012-2310-x.
   PubMed Web of Science ®Google Scholar
• Tullus K, Webb H, Bagga A. Management of steroid-resistant nephrotic syndrome in children and adolescents. Lancet Child Adolesc Health. 2018;2(12):880–890. doi:10.1016/S2352-4642(18)30283-9.
   PubMedGoogle Scholar
• Trautmann A, Schnaidt S, Lipska-Ziętkiewicz BS, Bodria M, Ozaltin F, Emma F, Anarat A, Melk A, Azocar M, Oh J, et al. Long-term outcome of steroid-resistant nephrotic syndrome in children. J Am Soc Nephrol. 2017;28(10):3055–3065. doi:10.1681/ASN.2016101121.
   PubMed Web of Science ®Google Scholar
• Büscher AK, Kranz B, Büscher R, Hildebrandt F, Dworniczak B, Pennekamp P, Kuwertz-Bröking E, Wingen A-M, John U, Kemper M, et al. Immunosuppression and renal outcome in congenital and pediatric steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol. 2010;5(11):2075–84. doi:10.2215/CJN.01190210.
   PubMed Web of Science ®Google Scholar
• Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, Chang J-M, Choi HY, Campbell KN, Kim K, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008;14(9):931–8. doi:10.1038/nm.1857.
   PubMed Web of Science ®Google Scholar
• Abou Daher A, El Jalkh T, Eid AA, Fornoni A, Marples B, Zeidan YH. Translational aspects of sphingolipid metabolism in renal disorders. Int J Mol Sci. 2017;18(12):2528. doi:10.3390/ijms18122528.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Hirono K, Aizawa T, Tsugawa K, Joh K, Imaizumi T, Tanaka H. Podocyte sphingomyelin phosphodiesterase acid-like 3b decreases among children with idiopathic nephrotic syndrome. Clin Exp Nephrol. 2021;25(1):44–51. doi:10.1007/s10157-020-01970-0.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Ikezumi Y, Saitoh A. Rituximab protects podocytes and exerts anti-proteinuric effects in rat adriamycin-induced nephropathy independent of B-lymphocytes. Nephrology (Carlton)). 2017;22(1):49–57. doi:10.1111/nep.12737.
   PubMed Web of Science ®Google Scholar
• Kim AH, Chung J-J, Akilesh S, Koziell A, Jain S, Hodgin JB, Miller MJ, Stappenbeck TS, Miner JH, Shaw AS, et al. B cell-derived IL-4 acts on podocytes to induce proteinuria and foot process effacement. JCI Insight. 2017;2(21). doi:10.1172/jci.insight.81836.
   Web of Science ®Google Scholar